CEPI works to develop vaccines against emerging infectious diseases. Our latest funding call aims to develop and manufacture proven vaccine technology for use against 2019-nCoV.
The rapid global spread and epidemiological characteristics of COVID-19 are deeply concerning. CEPI has moved quickly and urgently to coordinate with global health authorities and partners to rapidly develop vaccine candidates against the disease.
CEPI wants to galvanise the development of new vaccines against diseases we know could cause the next devastating epidemic.
The estimated annual global cost of moderately severe to severe pandemics
The number of diseases WHO identified as public health risks due to epidemic potential and lack of biomedical countermeasures
The minimum average cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases
CEPI (pronounced 'seppy') aims to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.
Ahmedabad, India (Paula Bronstein/Getty Images Reportage)
